|
Index of reports
> Cases with Thrombocytopenia (204)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Cyclophosphamide where reactions include thrombocytopenia. The selected reports were submitted to the FDA during the sample period of about a year. Reports 1 - 30 of 204 Next >>
Possible Cyclophosphamide side effects in 65 year old female
Reported by a physician from Japan on 2012-08-24
Patient: 65 year old female, weighing 50.2 kg (110.6 pounds)
Reactions: Weight Decreased, Blood Bilirubin Increased, Cytomegalovirus Viraemia, Headache, Pyrexia, Interstitial Lung Disease, Oedema, Thrombocytopenia, Blood Sodium Decreased, Decreased Appetite, Vomiting, Stomatitis, Pneumonia, Alanine Aminotransferase Increased, Lymphopenia, Anaemia, Febrile Neutropenia, Rash, Blood Phosphorus Decreased, Blood Potassium Decreased, Diarrhoea, Alopecia, Aspartate Aminotransferase Increased, Neutropenia, Leukopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Adriamycin PFS
Dosage: 30 mg/m2 x 1/4 week
Start date: 2011-03-16
Adriamycin PFS
Dosage: 40 mg/m2 x 1/4 week
Indication: Adult T-Cell Lymphoma / Leukaemia
Start date: 2011-03-09
Carboplatin
Dosage: 250 mg/m2 x 1/4 week
Indication: Adult T-Cell Lymphoma / Leukaemia
Start date: 2011-03-24
Cyclophosphamide
Dosage: 350 mg/m2 x 1/4 week
Indication: Adult T-Cell Lymphoma / Leukaemia
Start date: 2011-03-09
Etoposide
Dosage: 100 mg/m2 x 1/4 week
Indication: Adult T-Cell Lymphoma / Leukaemia
Start date: 2011-03-24
Prednisolone
Dosage: 40 mg/m2 x 1/4 week
Administration route: Oral
Indication: Adult T-Cell Lymphoma / Leukaemia
Start date: 2011-03-09
Prednisolone
Dosage: 1mg/kg x 1/2 week
Start date: 2011-12-13
End date: 2011-12-14
Prednisolone
Dosage: 40 mg/m2 x 1/4 week
Administration route: Oral
Start date: 2011-03-16
Prednisolone
Dosage: 2 mg/m2, 1x/day
Administration route: Oral
Start date: 2011-03-24
Ranimustine
Dosage: 60 mg/m2 x 1/4 week
Indication: Adult T-Cell Lymphoma / Leukaemia
Start date: 2011-03-16
Vincristine Sulfate
Dosage: 1 mg/m2 x 1/4 week
Indication: Adult T-Cell Lymphoma / Leukaemia
Start date: 2011-03-09
Vindesine Sulfate
Dosage: 2.4 mg/m2 x 1/4 week
Indication: Adult T-Cell Lymphoma / Leukaemia
Start date: 2011-03-24
Other drugs received by patient: Mucosolvan; Lansoprazole; Sulfamethoxazole and Trimethoprim; Armodafinil; Zolpidem; Olopatadine HCL; Cefazolin Sodium; Ciprofloxacin HCL; Armodafinil; Zovirax; Magmitt; Alendronate Sodium
Possible Cyclophosphamide side effects in male
Reported by a physician from United States on 2012-08-22
Patient: male
Reactions: Rectal Haemorrhage, Constipation, Cardiac Disorder, Hospitalisation, Granulocytopenia, Inappropriate Antidiuretic Hormone Secretion, Thrombocytopenia, Cardiac Failure Congestive, Pneumonia, Anaemia, Pancytopenia, Atrial Fibrillation, Febrile Neutropenia, Syncope, Embolism, Sepsis, Dehydration, Asthenia, Mantle Cell Lymphoma Recurrent, Leukopenia, Deep Vein Thrombosis, Infection
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1
Indication: Mantle Cell Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Indication: Mantle Cell Lymphoma
Leukine
Dosage: on day 9-15; 250 mcg/m2/day
Indication: Mantle Cell Lymphoma
Leukine
Dosage: on day 9-15; 250 mcg/m2/day
Indication: Diffuse Large B-Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Indication: Mantle Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: on day 15; as infusion
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: on day 15; as infusion
Indication: Mantle Cell Lymphoma
Vincristine
Dosage: on day 1 (maximum dose: 2mg)
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: on day 1 (maximum dose: 2mg)
Indication: Mantle Cell Lymphoma
Possible Cyclophosphamide side effects in 44 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-21
Patient: 44 year old female
Reactions: Squamous Cell Carcinoma, Carbohydrate Antigen 125 Increased, Thrombocytopenia
Drug(s) suspected as cause:
ABT-888
Administration route: Oral
Indication: Ovarian Cancer
Start date: 2010-06-01
End date: 2011-04-01
Carboplatin
Dosage: x 3 days for 4 cycles
Indication: Ovarian Cancer
Start date: 2007-07-13
End date: 2007-09-14
Cisplatin
Dosage: x 3 days for 4 cycles
Indication: Ovarian Cancer
Start date: 2005-06-14
End date: 2005-08-10
Cyclophosphamide
Indication: Ovarian Cancer
Start date: 2010-06-01
End date: 2011-04-01
Doxorubicin Hydrochloride
Dosage: maintenance dose for a total cumulative dose of 1.696 mg
Indication: Ovarian Cancer
End date: 2010-04-01
Doxorubicin Hydrochloride
Dosage: 3 cycles given
Start date: 2007-07-13
End date: 2007-09-14
Paclitaxel
Dosage: x 3 days for 4 cycles
Indication: Ovarian Cancer
Start date: 2007-07-13
End date: 2007-09-14
Topotecan Hydrochloride
Start date: 2005-08-29
Topotecan Hydrochloride
Dosage: for 4 cycles
Indication: Ovarian Cancer
Start date: 2005-06-14
End date: 2005-08-02
Possible Cyclophosphamide side effects in
Reported by a physician from United States on 2012-08-16
Patient:
Reactions: Nausea, Pain, Motor Dysfunction, Rash, Peripheral Sensory Neuropathy, Fatigue, Blood Potassium Decreased, Dyspepsia, Diarrhoea, Neutropenia, Thrombocytopenia
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1
Cyclophosphamide
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: B-Cell Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Doxorubicin HCL
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Indication: Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Doxorubicin HCL
Dosage: on day 1
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: B-Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Waldenstrom's Macroglobulinaemia
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphocytic Lymphoma
Rituximab
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Indication: Lymphocytic Lymphoma
Rituximab
Dosage: maintenance
Indication: B-Cell Lymphoma
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Indication: non-Hodgkin's Lymphoma
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Rituximab
Dosage: maintenance
Indication: Lymphoma
Rituximab
Dosage: on day 1
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: B-Cell Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Waldenstrom's Macroglobulinaemia
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: Lymphocytic Lymphoma
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Waldenstrom's Macroglobulinaemia
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: B-Cell Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphocytic Lymphoma
Other drugs received by patient: Acetaminophen; Diphenhydramine Hydrochloride; Ondansetron
Possible Cyclophosphamide side effects in female
Reported by a health professional (non-physician/pharmacist) from France on 2012-08-16
Patient: female
Reactions: Hepatic Pain, Hyperthermia, Bicytopenia, Weight Increased, Renal Failure, Hepatomegaly, Respiratory Failure, Staphylococcal Infection, Oliguria, Thrombocytopenia, Fluid Retention
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 3900 mg, unk
Indication: Product Used FOR Unknown Indication
Start date: 2012-06-03
Methotrexate
Dosage: 17.6 mg, unk
Start date: 2012-06-13
Methotrexate
Dosage: 26.5 unk, unk
Indication: Product Used FOR Unknown Indication
Start date: 2012-06-08
Methotrexate
Dosage: 17.6 mg, unk
Start date: 2012-06-10
Thymoglobulin
Dosage: 0.5 mg/kg, unk
Indication: Product Used FOR Unknown Indication
Start date: 2012-06-04
Thymoglobulin
Dosage: 2.5 mg/kg, unk
Start date: 2012-06-06
Thymoglobulin
Dosage: 2 mg/kg, unk
Start date: 2012-06-05
Possible Cyclophosphamide side effects in female
Reported by a consumer/non-health professional from France on 2012-08-14
Patient: female
Reactions: Hepatic Pain, Hyperthermia, Bicytopenia, Weight Increased, Hepatomegaly, Renal Failure, Staphylococcal Infection, Respiratory Failure, Oliguria, Thrombocytopenia, Fluid Retention
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 3900 mg, unk
Indication: Product Used FOR Unknown Indication
Start date: 2012-06-03
Methotrexate
Dosage: 17.6 mg, unk
Start date: 2012-06-10
Methotrexate
Dosage: 17.6 mg, unk
Start date: 2012-06-13
Methotrexate
Dosage: 26.5 unk, unk
Indication: Product Used FOR Unknown Indication
Start date: 2012-06-08
Thymoglobulin
Dosage: 0.5 mg/kg, unk
Indication: Product Used FOR Unknown Indication
Start date: 2012-06-04
Thymoglobulin
Dosage: 2 mg/kg, unk
Start date: 2012-06-05
Thymoglobulin
Dosage: 2.5 mg/kg, unk
Start date: 2012-06-06
Possible Cyclophosphamide side effects in female
Reported by a health professional (non-physician/pharmacist) from France on 2012-08-13
Patient: female
Reactions: Hepatomegaly, Thrombocytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Bone Marrow Transplant
Start date: 2012-04-03
End date: 2012-04-04
Cyclophosphamide
Start date: 2012-06-03
End date: 2012-06-04
Methotrexate
Start date: 2012-06-10
End date: 2012-06-10
Methotrexate
Indication: Bone Marrow Transplant
Start date: 2012-06-08
End date: 2012-06-08
Methotrexate
Start date: 2012-06-13
End date: 2012-06-13
Thymoglobulin
Indication: Bone Marrow Transplant
Start date: 2012-06-04
End date: 2012-06-06
Possible Cyclophosphamide side effects in
Reported by a physician from Netherlands on 2012-08-07
Patient:
Reactions: Diabetes Mellitus, Thrombocytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: unk
Indication: Multiple Myeloma
Start date: 2012-07-16
Dexamethasone
Dosage: unk
Indication: Multiple Myeloma
Start date: 2012-07-16
Velcade
Dosage: unk
Indication: Multiple Myeloma
Start date: 2012-07-16
Other drugs received by patient: Omeprazole; Fluconazole; Zelitrex / 01269701 /; Ciproxin / 00697201 /; Metoclopramide
Possible Cyclophosphamide side effects in
Reported by a physician from United States on 2012-08-01
Patient:
Reactions: Nausea, Motor Dysfunction, Pain, Rash, Peripheral Sensory Neuropathy, Fatigue, Dyspepsia, Blood Potassium Decreased, Diarrhoea, Neutropenia, Thrombocytopenia
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Cyclophosphamide
Dosage: on day 1
Indication: B-Cell Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Cyclophosphamide
Dosage: on day 1
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Lymphoma
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Doxorubicin Hydrochloride
Dosage: on day 1
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: B-Cell Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: B-Cell Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Waldenstrom's Macroglobulinaemia
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphocytic Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Rituximab
Dosage: maintenance
Indication: Waldenstrom's Macroglobulinaemia
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Rituximab
Dosage: on day 1
Indication: B-Cell Lymphoma
Rituximab
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Rituximab
Dosage: maintenance
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Indication: Lymphoma
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: non-Hodgkin's Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: B-Cell Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Lymphoma
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: Lymphocytic Lymphoma
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Waldenstrom's Macroglobulinaemia
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Waldenstrom's Macroglobulinaemia
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphocytic Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: B-Cell Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphoma
Other drugs received by patient: Diphenhydramine HCL; Acetaminophen; Ondansetron
Possible Cyclophosphamide side effects in female
Reported by a health professional (non-physician/pharmacist) from Germany on 2012-07-27
Patient: female, weighing 67.7 kg (148.9 pounds)
Reactions: Febrile Neutropenia, Neutropenia, Bronchitis, Thrombocytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Start date: 2012-05-24
Cyclophosphamide
Start date: 2012-04-12
Epirubicin Hydrochloride
Start date: 2012-05-24
Epirubicin Hydrochloride
Start date: 2012-04-12
Fluorouracil
Start date: 2012-04-12
Fluorouracil
Start date: 2012-05-24
Other drugs received by patient: Nobiten; Pantoprazole; Simvastatine EG; Escitalopram Oxalate
Possible Cyclophosphamide side effects in
Reported by a physician from Italy on 2012-07-27
Patient:
Reactions: Anaemia, Skin Toxicity, Febrile Neutropenia, Mucosal Inflammation, Neurotoxicity, Respiratory Failure, Sepsis, Neutropenia, Cardiotoxicity, Septic Shock, Thrombocytopenia, Myocardial Infarction, Diffuse Large B-Cell Lymphoma
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Indication: Diffuse Large B-Cell Lymphoma
Epirubicin Hydrochloride
Indication: Diffuse Large B-Cell Lymphoma
Mabthera
Indication: Diffuse Large B-Cell Lymphoma
Prednisone and Prednisone
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Possible Cyclophosphamide side effects in 46 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-27
Patient: 46 year old female
Reactions: Pancreatic Infarction, Unresponsive To Stimuli, Myelodysplastic Syndrome, Pyrexia, Pallor, Cerebral Haemorrhage, Skin Discolouration, Diarrhoea Haemorrhagic, Small Intestinal Haemorrhage, Apnoea, Thrombocytopenia, Cough, Candidiasis, Hepatosplenomegaly, Dyspnoea, Pain in Extremity, Anaemia, Pulmonary Haemorrhage, Zygomycosis, Diarrhoea, Hemisensory Neglect, Lung Infiltration, Asthenia, Hepatic Infarction
Adverse event resulted in: death
Drug(s) suspected as cause:
Carmustine
Indication: Diffuse Large B-Cell Lymphoma
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Cytarabine
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin Hydrochloride
Indication: Diffuse Large B-Cell Lymphoma
Etoposide
Indication: Diffuse Large B-Cell Lymphoma
Idarubicin HCL
Dosage: 12 mg/m2, unk
Indication: Myelodysplastic Syndrome
Oncovin
Indication: Diffuse Large B-Cell Lymphoma
Prednisone
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Indication: Diffuse Large B-Cell Lymphoma
Suberoylanilide Hydroxamic Acid
Dosage: 500 mg, tid
Administration route: Oral
Indication: Myelodysplastic Syndrome
Other drugs received by patient: Radiotherapy
Possible Cyclophosphamide side effects in 77 year old female
Reported by a physician from United States on 2012-07-24
Patient: 77 year old female, weighing 63.0 kg (138.7 pounds)
Reactions: Dyspnoea, Dysgeusia, Fatigue, Bronchial Disorder, Pleural Effusion, Weight Fluctuation, Neutropenia, Asthenia, Thrombocytopenia, Cardiac Failure Congestive
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: iv
Indication: non-Hodgkin's Lymphoma
Start date: 2012-05-01
Matulane
Dosage: 100 mg;qd;po
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Start date: 2012-05-21
Prednisone TAB
Dosage: po
Indication: non-Hodgkin's Lymphoma
Start date: 2012-05-01
Rituximab
Indication: non-Hodgkin's Lymphoma
Start date: 2012-05-01
Sodium Nitroprusside
Indication: non-Hodgkin's Lymphoma
Start date: 2012-05-01
Possible Cyclophosphamide side effects in
Reported by a physician from Italy on 2012-07-20
Patient:
Reactions: Anaemia, Febrile Neutropenia, Toxicity To Various Agents, Diffuse Large B-Cell Lymphoma Recurrent, Mucosal Inflammation, Neurotoxicity, Sepsis, Adverse Event, Cardiotoxicity, Neutropenia, Thrombocytopenia, Diffuse Large B-Cell Lymphoma, Lymphoma, Septic Shock
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 750 mg/m2 on day 1 for chop and 750 mg/m2 on day 2 for r-chop
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: 50 mg/m2 on day 1 for chop and 50 mg/m2 on day 2 for r-chop
Indication: Diffuse Large B-Cell Lymphoma
Prednisone
Dosage: 100 mg on days 1-5 for chop and r-chop
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: 375 mg/m2 on day 1 for r-chop
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: 1.4 mg/m2 on day 1 for chop and 1.4 mg/m2 on day 2 for r-chop upto a maximum dose of 2 mg
Indication: Diffuse Large B-Cell Lymphoma
Other drugs received by patient: Neupogen
Possible Cyclophosphamide side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-18
Patient:
Reactions: Pneumonia, Nausea, Lymphopenia, Hyperglycaemia, Anaemia, Febrile Neutropenia, Constipation, Renal Failure, Neuropathy Peripheral, Fatigue, Diarrhoea, Embolism, Neutropenia, Thrombocytopenia, Deep Vein Thrombosis
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 500 milligram/sq. meter
Indication: Multiple Myeloma
Dexamethasone
Dosage: 40 milligram
Indication: Multiple Myeloma
Revlimid
Dosage: 25 milligram
Administration route: Oral
Indication: Multiple Myeloma
Revlimid
Dosage: 15 milligram
Administration route: Oral
Velcade
Dosage: 1.3 milligram/sq. meter
Indication: Multiple Myeloma
Velcade
Dosage: 1.3 milligram/sq. meter
Possible Cyclophosphamide side effects in
Reported by a individual with unspecified qualification from United States on 2012-07-11
Patient:
Reactions: Weight Decreased, Thrombosis, Pruritus, Hypokalaemia, Fatigue, Depression, Thrombocytopenia, Alanine Aminotransferase Abnormal, Blood Antidiuretic Hormone Abnormal, Dyspnoea, Nausea, Lymphopenia, Haemoglobin Abnormal, Hyponatraemia, Febrile Neutropenia, Palmar-Plantar Erythrodysaesthesia Syndrome, Rash, Diarrhoea, Embolism, Blood Alkaline Phosphatase Abnormal, Dehydration, Neutropenia, Leukopenia
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on days 1-14
Administration route: Oral
Indication: Breast Cancer Metastatic
Xeloda
Dosage: beginning on day 8 and continuing to day 21 (total of 14 days)
Administration route: Oral
Indication: Breast Cancer Metastatic
Possible Cyclophosphamide side effects in female
Reported by a individual with unspecified qualification from Japan on 2012-07-09
Patient: female
Reactions: Aspartate Aminotransferase Increased, Alanine Aminotransferase Increased, Thrombocytopenia, Leukopenia
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: for metastatic patients
Indication: Breast Cancer
Cyclophosphamide
Dosage: as adjuvant therapy
Docetaxel
Indication: Breast Cancer
Epirubicin Hydrochloride
Dosage: adjuvant therapy
Indication: Breast Cancer
Fluorouracil
Dosage: adjuvant therapy
Fluorouracil
Dosage: adjuvant therapy
Indication: Breast Cancer
Herceptin
Indication: Breast Cancer
Methotrexate
Indication: Breast Cancer
Paclitaxel
Paclitaxel
Indication: Breast Cancer
Vinorelbine Tartrate
Indication: Breast Cancer
Xeloda
Indication: Breast Cancer
Possible Cyclophosphamide side effects in
Reported by a physician from United States on 2012-07-06
Patient:
Reactions: Stomatitis, Hepatic Failure, Palmar-Plantar Erythrodysaesthesia Syndrome, Febrile Neutropenia, Haematotoxicity, Cardiac Disorder, Neutropenia, Thrombocytopenia, Renal Failure Acute
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Doxil
Dosage: cohort 1: 20 mg/m2 cohort ii: 25 mg/m2 cohort iii: 30 mg/m2
Indication: Diffuse Large B-Cell Lymphoma
Neulasta
Dosage: on day 2 of a 14 day cycle
Indication: Diffuse Large B-Cell Lymphoma
Prednisone TAB
Dosage: day 1-5
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: on day 1
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: 2 mg max
Indication: Diffuse Large B-Cell Lymphoma
Possible Cyclophosphamide side effects in female
Reported by a physician from Germany on 2012-07-06
Patient: female
Reactions: Presyncope, Thrombocytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1483 mg, q2wk
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Doxorubicin HCL
Dosage: 100 mg, q2wk
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Neulasta
Dosage: 6 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-04-29
Prednisolone
Dosage: 100 mg, q2wk
Indication: B-Cell Lymphoma
Start date: 2012-04-26
End date: 2012-04-30
Rituxan
Dosage: 742.5 mg, q2wk
Indication: B-Cell Lymphoma
Start date: 2012-04-25
Vincristine
Dosage: 3.94 mg, q2wk
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Other drugs received by patient: Ramipril; Nebivolol; Tiotropium Bromide; Levothyroxine Sodium; Trimethoprim + Sulfamethoxazole; Acyclovir; Simvastatin; Torsemide; Acetylsalicylic Acid SRT; Enoxaparin Sodium; Pantoprazole
Possible Cyclophosphamide side effects in male
Reported by a pharmacist from Netherlands on 2012-07-06
Patient: male, weighing 80.0 kg (176.0 pounds)
Reactions: Colitis, Thrombocytopenia, Leukopenia, Renal Failure Acute
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Multiple Myeloma
Start date: 2012-05-04
Velcade
Indication: Multiple Myeloma
Start date: 2012-05-04
Other drugs received by patient: Fluconazole; Valaciclovir; Dexamethasone; Cotrim
Possible Cyclophosphamide side effects in
Reported by a physician from United States on 2012-07-05
Patient:
Reactions: Nausea, Anaemia, Chills, Constipation, Fatigue, Neuropathy Peripheral, Alopecia, Adverse Event, Neutropenia, Thrombocytopenia
Drug(s) suspected as cause:
Cyclophosphamide
Cyclophosphamide
Indication: Chronic Lymphocytic Leukaemia
Cyclophosphamide
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Indication: Chronic Lymphocytic Leukaemia
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: B-Cell Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Chronic Lymphocytic Leukaemia
Prednisone
Dosage: on days 1-5
Administration route: Oral
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Indication: B-Cell Lymphoma
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Indication: Chronic Lymphocytic Leukaemia
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Velcade
Dosage: on days 1 and 8
Velcade
Dosage: on days 1 and 8
Indication: Chronic Lymphocytic Leukaemia
Velcade
Dosage: on days 1 and 8
Indication: B-Cell Lymphoma
Possible Cyclophosphamide side effects in 67 year old male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-02
Patient: 67 year old male
Reactions: Weight Decreased, Anaemia, Acute Phosphate Nephropathy, Mental Status Changes, Hypercalcaemia, Hyperuricaemia, Haemodialysis, Tumour Lysis Syndrome, Renal Impairment, Oliguria, Leukocytosis, Thrombocytopenia, Decreased Appetite, Renal Failure Acute, Hepatosplenomegaly
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Chemotherapy
Dexamethasone Sodium Phosphate
Indication: Chemotherapy
Doxorubicin HCL
Indication: Chemotherapy
Vincristine
Indication: Chemotherapy
Possible Cyclophosphamide side effects in female
Reported by a physician from Germany on 2012-06-28
Patient: female
Reactions: White Blood Cell Count Decreased, C-Reactive Protein Increased, Sepsis, Hypotension, Presyncope, Neutropenia, Thrombocytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Doxorubicin HCL
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Mabthera
Indication: B-Cell Lymphoma
Start date: 2012-04-25
Neulasta
Dosage: daily dose 6 mg, 2 x(29 apr 2012+17 may 2012
Indication: B-Cell Lymphoma
Start date: 2012-04-29
Prednisolone
Dosage: frequency 1 times in 2 week for 5 days
Indication: B-Cell Lymphoma
Start date: 2012-04-26
End date: 2012-04-30
Vincristine
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Other drugs received by patient: Enoxaparin Natrium; Aspirin; Ramipril; Tiotropium Bromide; Nebivolol; Torsemide; Pantoprazole; Levothyroxine Sodium; Acyclovir; Simvastatin; Trimethoprim + Sulfamethoxazole
Possible Cyclophosphamide side effects in
Reported by a health professional (non-physician/pharmacist) from Canada on 2012-06-28
Patient:
Reactions: Neuropathy Peripheral, Adverse Drug Reaction, Neutropenia, Multiple Myeloma, Thrombocytopenia
Drug(s) suspected as cause:
Bortezomib
Dosage: post-induction therapy, days 1, 8, 15
Indication: Multiple Myeloma
Bortezomib
Dosage: induction therapy
Cyclophosphamide
Dosage: post induction therapy; days 1, 8, 15, 22
Administration route: Oral
Indication: Multiple Myeloma
Dexamethasone
Dosage: induction therapy
Dexamethasone
Dosage: maintainance therapy
Indication: Multiple Myeloma
Doxorubicin HCL
Dosage: induction therapy
Indication: Multiple Myeloma
Prednisone TAB
Dosage: post induction therapy; of a 28-day cycle
Indication: Multiple Myeloma
Possible Cyclophosphamide side effects in
Reported by a physician from France on 2012-06-27
Patient:
Reactions: Febrile Neutropenia, Neutropenia, Toxicity To Various Agents, Diffuse Large B-Cell Lymphoma, Thrombocytopenia
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1, every 21 days for 6 cycles
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1, every 21 days for 6 cycles
Indication: Diffuse Large B-Cell Lymphoma
Granulocyte Colony Stimulating Factor
Indication: Diffuse Large B-Cell Lymphoma
Prednisolone
Dosage: on days 1-5, every 21 days for 6 cycles
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: on day 1, every 21 days for 6 cycles
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: on day 1, every 21 days for 6 cycles
Indication: Diffuse Large B-Cell Lymphoma
Possible Cyclophosphamide side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-27
Patient:
Reactions: Nausea, Chills, Anaemia, Constipation, Neuropathy Peripheral, Fatigue, Alopecia, Adverse Event, Neutropenia, Thrombocytopenia
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Chronic Lymphocytic Leukaemia
Cyclophosphamide
Indication: B-Cell Lymphoma
Cyclophosphamide
Doxorubicin HCL
Dosage: on day 1
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Indication: Chronic Lymphocytic Leukaemia
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Chronic Lymphocytic Leukaemia
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: B-Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Rituximab
Dosage: maintenance
Rituximab
Dosage: maintenance
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Rituximab
Dosage: on day 1
Indication: Chronic Lymphocytic Leukaemia
Rituximab
Dosage: on day 1
Indication: B-Cell Lymphoma
Velcade
Dosage: on days 1 and 8
Indication: Chronic Lymphocytic Leukaemia
Velcade
Dosage: on days 1 and 8
Indication: B-Cell Lymphoma
Velcade
Dosage: on days 1 and 8
Possible Cyclophosphamide side effects in
Reported by a individual with unspecified qualification from Korea, Republic of on 2012-06-26
Patient:
Reactions: Abdominal Pain, Hyperbilirubinaemia, Anaemia, Alanine Aminotransferase Increased, Febrile Neutropenia, Rash, Pyrexia, Peripheral Sensory Neuropathy, Diarrhoea, Alopecia, Aspartate Aminotransferase Increased, Neutropenia, Asthenia, Thrombocytopenia
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: given on day 1 of each cycle
Indication: B-Cell Lymphoma
Mabthera
Dosage: on day 1 of every cycle
Indication: B-Cell Lymphoma
Prednisolone
Dosage: given on days 1 to 5 of every cycle (repeated every 3 weeks)
Administration route: Oral
Indication: B-Cell Lymphoma
Vincristine
Dosage: given on day 1 of every cycle; dose: 1.4 mg/m2 ( maximum 2.0 mg)
Indication: B-Cell Lymphoma
Possible Cyclophosphamide side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-22
Patient:
Reactions: Performance Status Decreased, Pain, Abdominal Pain Upper, Fatigue, Neutropenic Infection, Thrombocytopenia, Hallucination, Dyspnoea, Vomiting, Nausea, Hyperglycaemia, Haemoglobin Abnormal, Pancytopenia, Febrile Neutropenia, Toxicity To Various Agents, Haemoglobin, Neutropenia, Diffuse Large B-Cell Lymphoma, Cardiovascular Disorder, Leukopenia, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 6-8 cycles
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: 6-8 cycles
Indication: Diffuse Large B-Cell Lymphoma
Granulocyte Macrophage Colony Stim Factor
Dosage: days 3-10
Indication: Diffuse Large B-Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: 6-8 cycles
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: 6-8 cycles
Indication: Diffuse Large B-Cell Lymphoma
Other drugs received by patient: Anti-Emetics; Dapsone; Trimethoprim + Sulfamethoxazole
Possible Cyclophosphamide side effects in
Reported by a physician from United States on 2012-06-22
Patient:
Reactions: Ischaemia, Thrombosis, Hypersensitivity, Adverse Drug Reaction, Rectal Haemorrhage, Headache, Peripheral Sensory Neuropathy, Disease Progression, Cardiac Disorder, Myalgia, Fatigue, Proteinuria, Leukoencephalopathy, Thrombocytopenia, Epistaxis, Dyspnoea, Nausea, Alanine Aminotransferase Increased, Anaemia, Febrile Neutropenia, Mucosal Inflammation, Arthralgia, Aspartate Aminotransferase Increased, Ejection Fraction Decreased, Neutropenia, Hypertension
Drug(s) suspected as cause:
Bevacizumab
Indication: Breast Cancer
Cyclophosphamide
Indication: Breast Cancer
Doxorubicin HCL
Dosage: 10, 20, 50, 100 or 150mg vials
Indication: Breast Cancer
Doxorubicin Hydrochloride
Indication: Breast Cancer
Taxol
Indication: Breast Cancer
Other drugs received by patient: Radiation Therapy NOS; Hormonal Treatment NOS
Possible Cyclophosphamide side effects in male
Reported by a individual with unspecified qualification from Italy on 2012-06-18
Patient: male
Reactions: Epstein-Barr Virus Infection, Diarrhoea, Anaemia, Sepsis, Cytomegalovirus Infection, Neutropenia, Thrombocytopenia, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cisplatin
Indication: Burkitt's Lymphoma
Cyclophosphamide
Indication: Burkitt's Lymphoma
Cytarabine
Indication: Burkitt's Lymphoma
Doxorubicin Hydrochloride
Indication: Burkitt's Lymphoma
Etoposide
Indication: Burkitt's Lymphoma
Mabthera
Indication: Burkitt's Lymphoma
Methotrexate
Indication: Burkitt's Lymphoma
Methylprednisolone
Indication: Burkitt's Lymphoma
Vincristine Sulfate
Indication: Burkitt's Lymphoma
Page 1 Next >>
|
